Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma

Authors :: Stephen P. Hack
Claus Garbe
Michele Maio
Daniil Stroyakovskiy
Luc Thomas
James Larkin
Ilsung Chang
Gabriella Liszkay
Luis de la Cruz-Merino
Isabelle Rooney
Mario Mandalà
Caroline Dutriaux
Lev V. Demidov
Antoni Ribas
Grant A. McArthur
Brigitte Dréno
Victoria Atkinson
Paolo A. Ascierto
Yibing Yan
Matthew Wongchenko
Source :: Journal of Clinical Oncology. 33:9006-9006
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 9006 Background: Primary analysis of coBRIM showed significant improvement in PFS and overall response rate (ORR) in BRAFV600 mutation–positive patients (pts) with advanced melanoma treated with ve...

Full Text Access

Tools